A medical oncologist discusses standard-of-care treatment practices for patients with lower-risk myelodysplastic syndromes.
Videos
Neel Bhatt, MBBS, MPH, discusses a study exploring long-term quality of life outcomes of patients who underwent stem cell transplantation for aplastic anemia.
Matthew Hadfield, DO, discusses his interest in immunotherapy and the toxicities associated with them.
The panelists compare the adverse event profiles of immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens, and address the economic implications of managing long-term side effects.
Following recent updates from the SEQUOIA Arm D and CAPTIVATE studies, Mazyar Shadman, MD, MPH, discusses the future implications of fixed-duration therapy for patients with CLL/SLL.
An expert on hematologic malignancies discusses the ongoing CAPTIVATE trial evaluating ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL.
Daniel Rubin, PharmD, discusses key takeaways from a study exploring the use. of a clinical decision tool for biomarker documentation.
Taiga Nishihori, MD, discusses a study in which investigators evaluated patients with relapsed/refractory multiple myeloma who were hospitalized and treated with commercial ciltacabtagene autoleucel at Moffitt Cancer Center between May 2022 and May 2023.
Vincent Law, research associate at Moffitt Cancer Center, discusses the key takeaways and implications of this research.
Corey Cutler, MD, MPH, and Hannah Choe, MD, provide future perspectives on the development of axatilimab for patients with chronic GVHD.
Alexandra Gomez Arteaga, MD, discusses the rationale behind a retrospective study comparing Orca-T with posttransplant cyclophosphamide-based hematopoietic cell transplantation.
Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, provide closing thoughts on the evolving treatment landscape for HER-negative and HER2-low metastatic breast cancer.
A blood cancer specialist discusses the latest data from the SEQUOIA Arm D trial investigating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations.
Mazyar Shadman, MD, MPH, describes his clinical approach to treating patients with high-risk CLL/SLL, including those with or without del(17p) or TP53 mutations.
The key opinion leaders share their strategies for selecting systemic therapy, comparing immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) approaches, for previously untreated patients with advanced renal cell carcinoma.
Medical experts specializing in clear cell renal cell carcinoma examine the concept of treatment-free survival in immunotherapy/tyrosine kinase inhibitor (IO/TKI) regimens, addressing both the advantages and potential drawbacks.
Francis P. Worden, MD, discusses future plans to investigate combination therapies and other novel treatments in the thyroid cancer space.
Barbara O'Brien, MD, discusses the goals and results of a study investigating tucatinib, trastuzumab, and capecitabine for the treatment of leptomeningeal metastases in patients with HER2-positive breast cancer.
Elias Jabbour, MD, provides an overview of the significance of the FDA approval of ponatinib plus chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Martin H. Voss, MD, discusses the trajectory of the advanced renal cell carcinoma treatment landscape and provides clinical advice to community oncologists.
Denise Yardley, MD, discusses the takeaways and next steps of an analysis of the NATALEE trial investigating ribociclib in node-negative breast cancer.
Maya Dimitrova, MD, discusses areas of further research and unmet needs for patients with melanoma.
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the potential benefits of antibody-drug conjugates in urothelial cancer while acknowledging the need for more education and experience among physicians to optimize their use.
Experts on graft-vs-host disease discuss the potential role for axatilimab within current treatment algorithms.
A hematologist provides an overview of the AGAVE-201 trial investigating axatilimab in patients with chronic graft-vs-host disease.
Medical oncologists share clinical practices for selecting and sequencing TROP2-directed antibody-drug conjugates, highlighting ideal candidates for sacituzumab govitecan or datopotamab deruxtecan.
Experts on breast cancer offer comprehensive insights on findings from the TROPiCS-02 study investigating sacituzumab govitecan in patients with HR+/HER2- metastatic or locally recurrent inoperable breast cancer.
Nazli Dizman, MD, discusses the importance of the 3 main clauses of the language of respect guidelines in renal cell carcinoma.